Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein, beta 3, 31kDa (Connexin 31 (Cx31))
- Target
- Connexin 31 (Cx31)
- Molecular classification
- Ion channel, Gap junction protein, Connexin family
01
Overview
Gap junction protein beta-3 (Connexin 31) is a component of gap junctions—specialized intercellular channels formed by connexin subunits. These channels enable the diffusion of ions and small molecules between neighboring cells, supporting key processes like tissue homeostasis, cell growth, differentiation in the skin, and proper function of the inner ear. Mutations in GJB3 impair gap junction assembly and channel function, and are associated with non-syndromic hearing loss and erythrokeratodermia variabilis, a skin disorder. Connexin 31 also has roles in cell survival and proliferation in certain cancers
- Other names
- Connexin 31CX31GJB3DFNA2DFNA2BEKVEKVP1gap junction beta-3 protein31kDa gap junction protein
02
Mechanism of action
Drugs altering connexin function would impact gap junction channel activity, thereby modulating cell-cell communication, ion diffusion, and signaling
03
Biological functions
Direct intercellular communicationDiffusion of ions and small signaling moleculesRegulation of cell growth and differentiation (epidermis)Facilitation of hearing physiology (inner ear)Maintenance of tissue homeostasis
04
Disease associations
Non-syndromic hearing loss/deafnessErythrokeratodermia variabilis (hereditary skin disorder)Potential role in tumor biology (leukemia cell survival)
05
Safety considerations
Mutations may cause disrupted cell communication leading to skin and hearing disorders; no specific toxicity for therapeutics targeting GJB3 is described in available literature
06
Interacting drugs
None directly identified in current literature or databases as of the search results
07
Biomarkers
GJB3/Connexin 31 gene mutations as diagnostic biomarkers for non-syndromic hearing loss and erythrokeratodermia variabilis
Beyond the preview
Go deeper on Gap junction protein, beta 3, 31kDa (Connexin 31 (Cx31)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gap junction protein, beta 3, 31kDa (Connexin 31 (Cx31)).